Risk factors for high death and loss-to-follow-up rates among patients with multidrug-resistant tuberculosis at a programmatic management unit

Javaid A 1 , Shaheen Z 2 , Shafqat M 3 , Khan AH 4 , Ahmad N 5

Affiliations 

  • 1 Department of Pulmonology, Postgraduate Medical Institute, Peshawar, Pakistan
  • 2 Department of Pulmonology, Nishtar Hospital Multan, Punjab, Pakistan. Electronic address: dzshaheen@hotmail.com
  • 3 Programmatic Management Unit for Drug-Resistant TB, Nishtar Hospital Multan, Punjab, Pakistan
  • 4 Discipline of Clinical Pharmacy, School of Pharmaceutical Sciences, Universiti Sains Malaysia, Pulau Pinang, Malaysia
  • 5 Discipline of Clinical Pharmacy, School of Pharmaceutical Sciences, Universiti Sains Malaysia, Pulau Pinang, Malaysia; Faculty of Pharmacy, University of Balochistan, Quetta, Pakistan. Electronic address: nafeesuob@gmail.com
Am J Infect Control, 2017 Feb 01;45(2):190-193.
PMID: 27769706 DOI: 10.1016/j.ajic.2016.07.026

Abstract

Among 186 retrospectively evaluated patients with multidrug-resistant tuberculosis, 33.9% were cured, 6.6% completed treatment, 25% died, 18.3% were lost to follow-up, 2.2% failed treatment, and 13.8% were still undergoing treatment by the end of the study period. Rural residence was a risk factor for loss to follow-up (odds ratio [OR], 3.315; P = .016), whereas baseline body weight <40 kg (OR, 2.175; P = .042) and resistance to ofloxacin (OR, 2.889; P = .025) were risk factors for death. Despite programmatic management, treatment outcomes of the current cohort were distressing.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

MeSH terms
Similar publications